Kathrin Bauer

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. doi request reprint Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
    Kathrin Bauer
    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Cochrane Database Syst Rev 11:CD008079. 2012
  2. ncbi request reprint Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma
    Kathrin Bauer
    Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University Hospital of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 102:E1. 2010
  3. doi request reprint Alemtuzumab for patients with chronic lymphocytic leukaemia
    Nicole Skoetz
    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Cochrane Database Syst Rev 2:CD008078. 2012
  4. doi request reprint Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors
    Nicole Skoetz
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Natl Cancer Inst 103:E1. 2011
  5. ncbi request reprint Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
    Natali Pflug
    Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
    Blood 124:49-62. 2014

Collaborators

Detail Information

Publications5

  1. doi request reprint Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia
    Kathrin Bauer
    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Cochrane Database Syst Rev 11:CD008079. 2012
    ..However, the impact of these agents remains unclear, as there are hints for increased risk of severe infections...
  2. ncbi request reprint Eleventh biannual report of the Cochrane Haematological Malignancies Group: Focus on Hodgkin lymphoma
    Kathrin Bauer
    Cochrane Haematological Malignancies Group, First Department of Internal Medicine, University Hospital of Cologne, Kerpener Strasse 62, D 50924 Cologne, Germany
    J Natl Cancer Inst 102:E1. 2010
    ....
  3. doi request reprint Alemtuzumab for patients with chronic lymphocytic leukaemia
    Nicole Skoetz
    Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    Cochrane Database Syst Rev 2:CD008078. 2012
    ..Nowadays, monoclonal antibodies are added, especially alemtuzumab and rituximab. However, the impact of these agents remains unclear, as there are hints of an increased risk of severe infections...
  4. doi request reprint Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors
    Nicole Skoetz
    Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany
    J Natl Cancer Inst 103:E1. 2011
    ....
  5. ncbi request reprint Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
    Natali Pflug
    Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany
    Blood 124:49-62. 2014
    ..The studies were registered as follows: CLL1 trial (NCT00262782, http://clinicaltrials.gov), CLL4 trial (ISRCTN 75653261, http://www.controlled-trials.com), and CLL8 trial (NCT00281918, http://clinicaltrials.gov). ..